DIABECELL PAGE UPDATED 5/16
www.lctglobal.com is an Australian based company that has developed a proprietary technology called IMMUPEL which coats cells with a protective capsule that prevents attack by the patient’s immune system. They have applied this technology to the treatment of type 1 diabetes in a process they refer to as Diabecell.
Diabecell contains specially bred disease free pig (porcine) insulin producing cells which when transplanted into humans produces insulin in response to shifting blood glucose levels. It employs IMMUPEL to encapsulate the cells to avoid detection by the body’s immune system which eliminates the need for use of immuno-suppressive agents.
Diabecell is presently in late stage clinical trials for the treatment of type 1 diabetes.